Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Life Technologies Corporation Sees FY 2012 Guidance At Low End Of Prior Range
Life Technologies Corporation announced that based primarily on increased headwinds from currency and an incrementally more conservative outlook for its European operations, the Company is revising its fiscal 2012 guidance. The Company is now expecting its organic revenue growth to be at the low end of its previously provided range of 2% to 4% and non-GAAP earnings per share in a range of $3.90 to $4.00. The Company reported revenues of $3.741 billion in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $3.824 billion and EPS of $4.00 for fiscal 2012.
Latest Developments for Life Technologies Corp
- Life Technologies Corp Issues Q2 2013 Guidance Below Analysts' Estimates-Conference Call
- Thermo Fisher Scientific Inc To Buy Life Technologies Corp-Reuters
- Life Technologies Corp Acquires KDR Biotech Co., LTD
- Thermo Fisher Scientific Inc Bids For Life Technologies Corp; Blackstone Group LP, Carlyle Group LP And Other PE Firms Finalizing Offer-Reuters
Latest Key Developments in Biotechnology
- Bioxyne Ltd Announces Termination Of Proposed Acquisition Of Vitality Devices Pty Ltd
- Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Norda ASA Plans Delisting from Oslo Stock Exchange
- Stemline Therapeutics Inc Announces Closing Of $60 Million Public Offering Of Common Stock
- Share this
- Link this
- Digg this
Follow Reuters